FR17C1062I2 - Anticorps specifiques a l' humain cd22 et leurs utilisation therapeutiques et diagnostiques - Google Patents

Anticorps specifiques a l' humain cd22 et leurs utilisation therapeutiques et diagnostiques

Info

Publication number
FR17C1062I2
FR17C1062I2 FR17C1062C FR17C1062C FR17C1062I2 FR 17C1062 I2 FR17C1062 I2 FR 17C1062I2 FR 17C1062 C FR17C1062 C FR 17C1062C FR 17C1062 C FR17C1062 C FR 17C1062C FR 17C1062 I2 FR17C1062 I2 FR 17C1062I2
Authority
FR
France
Prior art keywords
therapeutic
specific antibodies
diagnostic uses
disclosed
human specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR17C1062C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9935990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR17C1062(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB SA filed Critical UCB SA
Publication of FR17C1062I1 publication Critical patent/FR17C1062I1/fr
Application granted granted Critical
Publication of FR17C1062I2 publication Critical patent/FR17C1062I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR17C1062C 2002-05-02 2017-12-21 Anticorps specifiques a l' humain cd22 et leurs utilisation therapeutiques et diagnostiques Active FR17C1062I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0210121.0A GB0210121D0 (en) 2002-05-02 2002-05-02 Biological products
PCT/GB2003/001934 WO2003093320A2 (en) 2002-05-02 2003-05-02 Antibodies specific for human cd22 and their therapeuatic and digagnostic uses

Publications (2)

Publication Number Publication Date
FR17C1062I1 FR17C1062I1 (pm) 2018-02-16
FR17C1062I2 true FR17C1062I2 (fr) 2020-05-29

Family

ID=9935990

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C1062C Active FR17C1062I2 (fr) 2002-05-02 2017-12-21 Anticorps specifiques a l' humain cd22 et leurs utilisation therapeutiques et diagnostiques

Country Status (34)

Country Link
US (8) US7355011B2 (pm)
EP (1) EP1504035B9 (pm)
JP (3) JP4486494B2 (pm)
KR (3) KR101386376B1 (pm)
CN (3) CN103172742B (pm)
AT (1) ATE462729T3 (pm)
AU (1) AU2003223007C1 (pm)
BE (1) BE2017C068I2 (pm)
CA (1) CA2484420C (pm)
CO (1) CO5631451A2 (pm)
CY (3) CY1110134T1 (pm)
DE (1) DE60331910D1 (pm)
DK (1) DK1504035T6 (pm)
EC (1) ECSP045470A (pm)
ES (1) ES2341708T7 (pm)
FR (1) FR17C1062I2 (pm)
GB (1) GB0210121D0 (pm)
HU (2) HUS1700055I1 (pm)
IL (1) IL164923A (pm)
LT (2) LTC1504035I2 (pm)
LU (2) LUC00057I2 (pm)
MX (1) MXPA04010787A (pm)
NL (1) NL300920I2 (pm)
NO (3) NO336201B1 (pm)
NZ (1) NZ536757A (pm)
PL (1) PL218433B1 (pm)
PT (1) PT1504035E (pm)
RU (1) RU2342401C2 (pm)
SG (1) SG161744A1 (pm)
SI (1) SI1504035T1 (pm)
TW (1) TWI324161B (pm)
UA (1) UA92580C2 (pm)
WO (1) WO2003093320A2 (pm)
ZA (1) ZA200408851B (pm)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2461351C (en) * 2001-09-26 2014-08-05 Ira H. Pastan Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
DE60334364D1 (de) 2002-02-21 2010-11-11 Univ California Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
PT2371392E (pt) 2002-05-02 2015-10-07 Wyeth Holdings Llc Conjugados de derivado da caliqueamicina - transportador
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
SV2006002258A (es) * 2004-10-08 2006-09-19 Wyeth Corp Inmunoterapia de trastornos autoinmunes
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007103469A2 (en) 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US7829086B2 (en) 2006-03-06 2010-11-09 Medimmune, Llc Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2446904B1 (en) * 2006-05-30 2015-04-29 Genentech, Inc. Anti-CD22 antibodies, their immunoconjugates and uses thereof
BRPI0717902A2 (pt) * 2006-12-01 2013-10-29 Medarex Inc "anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo"
US8591889B2 (en) 2008-04-04 2013-11-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies specific for CD22
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
RU2606016C2 (ru) 2011-01-14 2017-01-10 Редвуд Байосайнс, Инк. Меченые альдегидом полипептиды иммуноглобулина и способы их применения
RU2013140975A (ru) 2011-02-28 2015-04-10 Дженентек, Инк. Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
KR20150008080A (ko) 2012-04-26 2015-01-21 바이오아트라, 엘엘씨 항-cd22 항체
NZ703423A (en) 2012-07-03 2018-02-23 Univ Washington Antibodies to tau
KR102165464B1 (ko) 2012-07-19 2020-10-14 레드우드 바이오사이언스 인코포레이티드 Cd22에 대해 특이적인 항체 및 이들의 사용 방법
EP2912061B1 (en) * 2012-10-24 2019-02-06 The United States of America, as represented by The Secretary, Department of Health and Human Services M971 chimeric antigen receptors
CN103214578B (zh) * 2013-05-10 2014-05-28 北京东方百泰生物科技有限公司 一种新型的人源化抗cd22抗体
EP3065780A1 (en) 2013-11-04 2016-09-14 Pfizer Inc. Anti-efna4 antibody-drug conjugates
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP4056588B1 (en) * 2015-04-08 2024-09-25 Novartis AG Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
ES2908470T3 (es) 2015-11-09 2022-04-29 Scherer Technologies Llc R P Conjugados de anticuerpo anti-CD22-maitansina y métodos de uso de los mismos
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
CA3019398A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
KR102413592B1 (ko) 2016-10-21 2022-06-27 암젠 인크 약학적 제형 및 그의 제조 방법
EP3774919A4 (en) 2018-03-30 2021-12-29 Eureka Therapeutics, Inc. Constructs targeting cd22 and uses thereof
US20230174654A1 (en) * 2020-04-02 2023-06-08 Nanjing Iaso Biotherapeutics Co., Ltd. Fully human anti-human cd22 chimeric antigen receptor and application thereof
CN114106177B (zh) * 2020-08-27 2024-04-09 深圳市菲鹏生物治疗股份有限公司 Cd22抗体及其应用
WO2022262783A1 (zh) * 2021-06-16 2022-12-22 西安宇繁生物科技有限责任公司 抗cd22的全人源抗体或其抗原结合片段及其制备方法和应用
JP2024534148A (ja) * 2021-08-27 2024-09-18 ペプトロン インコーポレイテッド 新規抗ｍｕｃ１抗体およびその用途
CN119751680A (zh) * 2021-12-06 2025-04-04 重庆精准生物技术有限公司 靶向cd22的抗原结合片段和单链抗体及其应用
US20240166705A1 (en) 2022-11-07 2024-05-23 Xencor, Inc. Il18-fc fusion proteins

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957362A (en) * 1972-10-02 1976-05-18 Corneal Sciences, Inc. Hydrogels and articles made therefrom
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU8221191A (en) * 1990-06-27 1992-01-23 Princeton University Probes for detecting mutant p53
ES2204890T3 (es) * 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5714340A (en) * 1992-12-22 1998-02-03 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassay elements having a receptor zone
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
DK1759709T3 (da) 1994-01-25 2013-06-10 Elan Pharm Inc Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4
CA2195557C (en) * 1994-08-12 2006-10-17 Shui-On Leung Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
WO1996005306A2 (en) 1994-08-12 1996-02-22 Myriad Genetics, Inc. IN VIVO MUTATIONS AND POLYMORPHISMS IN THE 17q-LINKED BREAST AND OVARIAN CANCER SUSCEPTIBILITY GENE
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20020141990A1 (en) * 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
EP0977590A4 (en) * 1996-11-01 2001-03-14 Smithkline Beecham Corp HUMAN MONOCLONAL ANTIBODIES
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
DE69838979T2 (de) * 1997-03-20 2008-12-24 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CA2635352C (en) 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
KR100345463B1 (ko) * 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
DE60042785D1 (de) * 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
ATE236398T1 (de) * 1999-10-12 2003-04-15 Connex Ges Zur Optimierung Von Verbessertes verfahren zum nachweis von säure- resistenten bakterien der gattung helicobacter im stuhl
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
AU6461201A (en) * 2000-07-12 2002-01-21 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
CN1205479C (zh) * 2000-10-31 2005-06-08 杨梦甦 免疫学诊断蛋白芯片制备方法
PT2371392E (pt) * 2002-05-02 2015-10-07 Wyeth Holdings Llc Conjugados de derivado da caliqueamicina - transportador
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
WO2007103469A2 (en) * 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Also Published As

Publication number Publication date
PL373277A1 (en) 2005-08-22
LTPA2017044I1 (lt) 2018-01-10
CN103172742A (zh) 2013-06-26
US7355011B2 (en) 2008-04-08
NO20044742L (no) 2004-12-22
EP1504035B1 (en) 2010-03-31
KR20050025167A (ko) 2005-03-11
LTC1504035I2 (lt) 2022-04-11
KR101238970B1 (ko) 2013-03-04
JP5377173B2 (ja) 2013-12-25
EP1504035B3 (en) 2017-12-20
AU2003223007B2 (en) 2009-07-16
ATE462729T3 (de) 2010-04-15
DK1504035T3 (da) 2010-06-07
LUC00057I1 (pm) 2017-12-27
JP4486494B2 (ja) 2010-06-23
EP1504035B9 (en) 2018-10-17
IL164923A (en) 2012-03-29
SI1504035T1 (sl) 2010-07-30
CN103172742B (zh) 2016-05-11
RU2342401C2 (ru) 2008-12-27
JP5920934B2 (ja) 2016-05-18
FR17C1062I1 (pm) 2018-02-16
CY1110134T1 (el) 2015-01-14
PT1504035E (pt) 2010-06-07
EP1504035B8 (en) 2018-02-28
RU2004135103A (ru) 2005-10-27
CY2017046I1 (el) 2018-12-12
PL218433B1 (pl) 2014-12-31
LUC00057I2 (pm) 2018-02-26
HK1186479A1 (zh) 2014-03-14
NZ536757A (en) 2006-06-30
DK1504035T6 (en) 2018-03-12
CN1662558A (zh) 2005-08-31
KR20110004463A (ko) 2011-01-13
US20160326247A1 (en) 2016-11-10
EP1504035A2 (en) 2005-02-09
US8895714B2 (en) 2014-11-25
JP2006506955A (ja) 2006-03-02
ZA200408851B (en) 2006-01-25
UA92580C2 (ru) 2010-11-25
CY2017046I2 (el) 2018-12-12
WO2003093320A3 (en) 2004-02-05
TW200307690A (en) 2003-12-16
US20120302739A1 (en) 2012-11-29
ECSP045470A (es) 2005-01-28
LUC00058I2 (pm) 2018-02-26
CY2017045I2 (el) 2019-11-27
US20110165659A1 (en) 2011-07-07
DE60331910D1 (de) 2010-05-12
US7919606B2 (en) 2011-04-05
CA2484420A1 (en) 2003-11-13
MXPA04010787A (es) 2005-03-07
KR101156796B1 (ko) 2012-06-21
IL164923A0 (en) 2005-12-18
KR101386376B1 (ko) 2014-04-16
LTPA2017043I1 (lt) 2018-01-10
US20030235869A1 (en) 2003-12-25
NO2017069I1 (no) 2017-12-21
LUC00058I1 (pm) 2017-12-27
ES2341708T7 (es) 2018-04-11
CO5631451A2 (es) 2006-04-28
NO2017068I1 (no) 2017-12-21
HUS1700055I1 (hu) 2018-07-30
CN101134779B (zh) 2013-03-13
US20100021995A1 (en) 2010-01-28
ES2341708T3 (es) 2010-06-25
HUS1700056I1 (hu) 2018-07-30
HK1071762A1 (en) 2005-07-29
TWI324161B (en) 2010-05-01
WO2003093320A2 (en) 2003-11-13
CN101134779A (zh) 2008-03-05
KR20120127513A (ko) 2012-11-21
NO336201B3 (no) 2015-06-15
CN100384878C (zh) 2008-04-30
AU2003223007A1 (en) 2003-11-17
US20170145114A1 (en) 2017-05-25
US20070059307A1 (en) 2007-03-15
GB0210121D0 (en) 2002-06-12
US20210371547A1 (en) 2021-12-02
NL300920I2 (nl) 2021-04-15
SG161744A1 (en) 2010-06-29
BE2017C068I2 (pm) 2022-08-09
JP2010022372A (ja) 2010-02-04
CY2017045I1 (el) 2019-11-27
AU2003223007C1 (en) 2019-08-08
CA2484420C (en) 2014-09-16
JP2013230158A (ja) 2013-11-14
NO336201B1 (no) 2015-06-15
NL300920I1 (pm) 2018-01-03

Similar Documents

Publication Publication Date Title
FR17C1062I2 (fr) Anticorps specifiques a l' humain cd22 et leurs utilisation therapeutiques et diagnostiques
MY136603A (en) Biological products
DE60237778D1 (de) Antikörper gegen kdr, deren herstellung und verwendungen
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
IL145535A0 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.